A STUDY COMPARING MAINTENANCE SUBCUTANEOUS RITUXIMAB WITH OBSERVATION ONLY IN PARTICIPANTS WITH RELAPSED OR REFRACTORY INDOLENT NON-HODGKIN'S LYMPHOMA WHO HAD RESPONDED TO RITUXIMAB-BASED IMMUNOCHEMOTHERAPY INDUCTION AND 2-YEAR MAINTENANCE WITH SUBCUTANEOUS RITUXIMAB: